World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
124
Citations
58048
World Ranking
3221
National Ranking
89

Isabelle Ray-Coquard publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Isabelle Ray-Coquard sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 991 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Isabelle Ray-Coquard D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Isabelle Ray-Coquard sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 124 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Isabelle Ray-Coquard is affiliated with Claude Bernard University Lyon 1 in France, with a primary focus on medical research related to oncology and reproductive medicine. Their extensive body of work spans across multiple subfields including oncology, reproductive medicine, obstetrics and gynecology, molecular biology, and pulmonary and respiratory medicine.

The scientist's research addresses key topics such as ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, endometrial and cervical cancer treatments, sarcoma diagnosis and treatment, uterine myomas and treatments, DNA repair mechanisms, and BRCA gene mutations in cancer.

Frequent coauthors collaborating with Isabelle Ray-Coquard include Nicoletta Colombo, Jean-Yves Blay, Ignace Vergote, Éric Pujade-Lauraine, and Isabelle Treilleux.

Their research has appeared in various academic journals, with a strong presence in the following venues:

  • International Journal of Gynecological Cancer
  • Gynecologic Oncology
  • Cancers
  • Annals of Oncology
  • European Journal of Cancer

Notable recent publications include:

  • Endometrial cancer, 2021, Nature Reviews Disease Primers
  • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer, 2020, Annals of Oncology
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial, 2021, The Lancet Oncology
  • The forefront of ovarian cancer therapy: update on PARP inhibitors, 2020, Annals of Oncology
  • Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology

With a research output including over 660 publications primarily in the field of medicine, Isabelle Ray-Coquard has contributed significantly to the understanding and treatment of gynecological cancers and related conditions.

Best Publications

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

    Andreas du Bois;Alexander Reuss;Eric Pujade-Lauraine;Philipp Harter

  • Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

    Eric Pujade-Lauraine;Felix Hilpert;Beatrice Weber;Alexander Reuss

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    Isabelle Ray-Coquard;Patricia Pautier;Sandro Pignata;David Pérol

  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    N. Colombo;C. Sessa;A. du Bois;J. Ledermann

  • Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

    Michael Gobert;Isabelle Treilleux;Nathalie Bendriss-Vermare;Thomas Bachelot

  • Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

    Thomas Bachelot;Céline Bourgier;Claire Cropet;Isabelle Ray-Coquard

  • Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

    Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

    Julia Bohlius;Kurt Schmidlin;Corinne Brillant;Guido Schwarzer

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

    Isabelle Ray-Coquard;Jean-Yves Blay;Antoine Italiano;Axel Le Cesne

  • Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

    Nicolas Penel;Binh Nguyen Bui;Jacques-Olivier Bay;Didier Cupissol

  • Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

    Françoise Ducimetière;Antoine Lurkin;Dominique Ranchère-Vince;Anne-Valérie Decouvelaere

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

    A. Le Cesne;J.Y. Blay;I. Judson;A. Van Oosterom

  • Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

    Jean-Yves Blay;Axel Le Cesne;Isabelle Ray-Coquard;Binh Bui

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

    N Colombo;N Colombo;C Sessa;A du Bois;J Ledermann

  • Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3

    Andreas du Bois;Alexander Reuss;Eric Pujade-Lauraine;Philipp Harter

Frequent Co-Authors

Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy
Antoine Italiano
Antoine Italiano University of Bordeaux
François Bertucci
François Bertucci Aix-Marseille University
Christine Chevreau
Christine Chevreau DuPont (United States)
Jean-Michel Coindre
Jean-Michel Coindre University of Bordeaux
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Sandro Pignata
Sandro Pignata National Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several related online degrees and career pathways that could broaden your skills and open up new opportunities. Many students look to fields like healthcare administration, pharmacy, or advanced nursing to complement their medical education.

Pursuing a health care administration online degree can prepare you for leadership roles in hospitals, clinics, and other medical facilities. For those seeking specialized management positions, there are also most affordable mha programs that offer comprehensive training in healthcare policy, finance, and operations.

Nursing professionals interested in clinical leadership might explore cheap online dnp programs, which provide a pathway to the highest levels of nursing practice. Additionally, for those fascinated by pharmaceuticals and patient care, a 3-year online pharmd program can help you earn your Doctor of Pharmacy credentials more flexibly and affordably.

These degrees offer flexible study options, affordability, and career advancement in various healthcare sectors—important factors to consider on your journey in medicine.

Best Scientists Citing Isabelle Ray-Coquard

Trending Scientists